Becton Dickinson raises 2026 profit forecast on demand
Becton Dickinson raised its annual profit forecast and beat quarterly estimates as demand for injection pens used for GLP-1 therapies remains high. The medical device maker expects adjusted 2026 earnings between $12.52 and $12.72 per share while appointing Vitor Roque as its permanent CFO.
Xurve View
Insights:
Xurve View
Becton Dickinson and Co raised its 2026 adjusted profit forecast to $12.72 per share after beating second-quarter earnings estimates on Thursday afternoon. Shares rose 5% as demand for GLP-1 injection pens and surgical equipment offset rising raw material costs. Cost pressures from higher oil and resin prices linked to the Middle East conflict are a key focus for investors tracking the medical supplier's margin sustainability.
